• About
  • Subscribe
  • Advertise
  • Contact
Monday, June 23, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home News

Glaukos trials eyelid cream to treat presbyopia and dry eye

by Staff Writer
January 19, 2022
in Business, Company updates & acquisitions, Dry eye, International, News, Ophthalmology, Optometry, Research, Therapeutics, Therapies
Reading Time: 3 mins read
A A
The active ingredient is delivered through the dermis of the eyelid to the eye.

The active ingredient is delivered through the dermis of the eyelid to the eye.

Share on FacebookShare on Twitter

Glaukos has commenced Phase 2 trials of two investigational cream-based drug candidates that are applied to the eyelids to treat dry eye and presbyopia.

This month the New York Stock Exchange-listed ophthalmic medical technology and pharmaceutical company announced it has enrolled the first patient into a Phase 2 study of GLK-301 for the treatment of signs and symptoms of dry eye disease (DED).

On the same day, it also revealed the first patient had enrolled in a Phase 2 clinical trial of GLK-302 for presbyopia.

Both therapies feature Glaukos’ iLution platform – patented cream-based drug formulations applied to the outer surface of the eyelid. In GLK-301 and GLK-302, the cream formulation acts as a depot allowing the active pharmaceutical ingredient pilocarpine to be delivered through the dermis of the eyelid to the eye.

In patients diagnosed with DED, the Phase 2 multi-centre, randomised, double-masked, placebo-controlled trial will evaluate the safety and efficacy of three different dose levels of GLK-301 administered twice daily to the eyelids versus placebo over 28 days, followed by a 14-day safety follow-up period.

Endpoints will include standard signs and symptoms characteristic of DED. The company anticipates it will enrol approximately 200 DED patients across clinical sites in the US. Additionally, approximately 20 patients with a diagnosis of DED due to Sjogren’s syndrome will be enrolled.

“[This] announcement represents a significant milestone in the development of our iLution platform and for our company,” Mr Thomas Burns, Glaukos president and CEO, said.

“We believe our iLution platform has the potential to address the major unmet need for patients suffering from dry eye disease and other chronic eye diseases by providing an effective, easy-to-administer, safe, dropless transdermal therapeutic.”

The presbyopia Phase 2 trial is designed to evaluate the safety and efficacy of three different dose levels of GLK-302 administered twice daily to the eyelid versus placebo over 28 days, for improving mesopic, high-contrast, binocular distance corrected near visual acuity while not deteriorating binocular best corrected distance visual acuity in presbyopic patients.

The company anticipates approximately 120 presbyopic patients will participate in the study across America.

“The dosing of the first patient in the Phase 2 study brings us one step closer to an innovative near vision solution for the millions of patients who suffer from presbyopia,” Burns stated.

“We are privileged to have the opportunity to explore what GLK-302 can do for presbyopic patients in our Phase 2 trial.”

More reading

FDA approves first presbyopia eye drop

New rules allowing optometrists to prescribe lifitegrast dry eye therapy

Access to dry eye treatments in Australia

Tags: dry eye diseaseGlaukosGLK-301GLK-302iLution platformophthalmic medical technologyPresbyopiaSjogren’s syndrome

Related Posts

Dr William Blase assessing scans obtained on the Optos MonacoPro. Images: Image: California Eye Professionals & Optos.

Early insights into the new Optos MonacoPro

by Staff Writer
June 23, 2025

Optos’ latest system is so new that Insight took its search global to find an ophthalmologist who has installed the...

Collective bargaining on consult times and KPIs are a focus of the group. Image: H_Ko/stock.adobe.com.

Hundreds of optometrists have joined Health Services Union

by Staff Writer
June 19, 2025

Hundreds of Australian optometrists have signed up to the Health Services Union (HSU) in the past few months, according to...

Doug Perkins Specsavers

Specsavers founder Doug Perkins receives top honour from King Charles

by Staff Writer
June 19, 2025

Specsavers co-founder and chair Mr Doug Perkins has been made a Commander of the Order of the British Empire by...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited